Spyre Therapeutics, Inc. (3920)

Profile

https://www.spyre.com

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment durability, and simplify dosing for patients with ulcerative colitis, Crohn’s disease, and related rheumatic conditions. Its current pipeline centers on investigational antibody programs targeting key immune pathways, including α4β7, TL1A, and IL-23, with both standalone and combination approaches under development. The company is primarily engaged in biopharmaceutical research and clinical development, and its work is centered on creating next-generation immunology treatments for complex chronic diseases. Headquartered in Waltham, Massachusetts, Spyre Therapeutics serves as a specialized player in the biotech sector, where it contributes to the advancement of targeted therapies for gastrointestinal and immune-mediated diseases.